Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Int J Rheumatol. 2011;2011:845496. doi: 10.1155/2011/845496. Epub 2011 Nov 22.

Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature.

Author information

  • 1Rheumatology Unit Department of Internal Medicine, Hospital S. Giovanni di Dio, Azienda Sanitaria di Firenze, 50143 Florence, Italy.

Abstract

The cost effectiveness of treatments that have changed the "natural history" of a chronic progressive disease needs to be evaluated over the long term. Disease-modifying antirheumatic drugs (DMARDs) are the standard treatment of rheumatoid arthritis (RA) and should be started as early as possible. A number of studies have shown that they are effective in improving disease activity and function, and in joint damage. Our review was focused on revision and critical evaluation of the studies including the literature on cost effectiveness of DMARDs (cyclosporine A, sulphasalazine, leflunomide, and methotrexate). The European League Against Rheumatism (EULAR) recommendations showed that traditional DMARDs are cost effective at the time of disease onset. They are less expensive than biological DMARDs and can be useful in controlling disease activity in early RA.

PMID:
22162693
[PubMed]
PMCID:
PMC3228304
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk